Concepedia

David Rinaldi

DR

26

Publications

2.3K

Citations

21

H-Index

1993

Active since

Affiliations

The University of Texas Health Science Center at San Antonio(Current)

Brooke Army Medical Center

Louisiana Hematology Oncology Associates

UPMC Hillman Cancer Center

Joint Base San Antonio

David Rinaldi is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, oncology, and pharmacotherapy.

Top concepts

Publications per year

1993–2008

26

Publications

26

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Mace L. Rothenberg, John R. Eckardt, John G. Kuhn et al. · Journal of Clinical Oncology · 1996 · 351 citations

Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer

Charles S. Fuchs, M. R. Moore, Graydon Harker et al. · Journal of Clinical Oncology · 2003 · 298 citations

Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

Chandra P. Belani, John Barstis, Michael C. Perry et al. · Journal of Clinical Oncology · 2003 · 205 citations

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

David Rinaldi, John G. Kuhn, Howard A. Burris et al. · Cancer Chemotherapy and Pharmacology · 1999 · 174 citations

, , +10

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

David Rinaldi, Howard A. Burris, F. Andrew Dorr et al. · Journal of Clinical Oncology · 1995 · 152 citations

Rows per page

1–5 of 26